BioControl - New generation of active implantable devices affecting the behavior of muscles and nerves of the autonomic nervous system. The company sold its urology business for $90M to American Medical Systems.
Missing: BioControl's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioControl's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioControl
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioControl is included in 1 Expert Collection, including Advanced Materials.
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
BioControl has filed 1 patent.
Bacteriophages, Molecular biology, Virology, Antibiotics, Piperazines
Bacteriophages, Molecular biology, Virology, Antibiotics, Piperazines
Latest BioControl News
Nov 17, 2022
The global biocontrol market is estimated to be valued at USD 6.6 Billion in 2022 and is projected to reach USD 13.7 Billion by 2027, recording a CAGR of 15.8% Biocontrol crop protection solutions consist of naturally occurring substances, including biochemicals (semiochemicals, plant extracts, organic acids), microorganisms (microbial biocontrols), and macrobials (beneficial insects) that control pests and support plant growth. Conventional chemical pesticides which have a larger market share at present in the crop protection market, have greater efficiency but are harmful to human and environmental health. Moreover, they have also created a rise in pest resistance. Thus, policy makers across the globe are regulating and banning chemical-based active ingredients, especially in the North American and European regions. This is driving the biocontrol market. Consumer awareness and the rise in demand for organic food are also the major factors that support the rise of the market in coming times. Europe is projected to witness the growth of 16.5% during the forecast period making it the fastest-growing market. The biocontrol market in Europe is growing at a CAGR of 16.5%. The European market has stringent import regulations and strictly monitors residue issues in food items. The market has a high organic food demand which is catered by domestic and international markets. The EU is also undertaking measures that are inclined towards food safety and environmental sustainability. For example, its Farm to Fork Strategy which is aimed to make food systems fair, healthy, and environment friendly. The European Commission had suggested a 50% reduction in the usage of chemical pesticides by 2030 in June 2022. The demand for organic food and consequently safe pesticides derived from nature is being driven by all these policies and activities. Therefore, Europe is a lucrative market for biocontrol solutions and is projected to grow at the fastest rate in the coming times. Biopesticides segment is projected to grow at a CAGR of 15.9% during the forecast period. Biopesticides are seen as a strong alternative to chemical pesticides. Due to rising regulations on chemical pesticides by regulatory bodies, biopesticides are gaining popularity in the market and replacing many chemical based pesticides especially in the North American and European markets. Biopesticides are also witnessing a fast growth in Asia Pacific and South American markets. Thus, various key players and startups in the biocontrol industry such as BASF SE (Germany), Bayer AG (Germany), Syngenta AG (Switzerland), Marrone Bio Innovations (US), and FMC Corporation (US) are developing and commercializing new biopesticides solutions. As a result, biopesticides segment in the biocontrol market is forecasted to grow at the fastest rate with a CAGR OF 15.9% during the forecast period. Pest developing resistance to crop chemicals is creating opportunities in the biocontrol market. Plant pathogenic bacteria, fungus, and insect pests are developing chemical resistance, and they are able to mutate to become resistant to crop protection agents. As a result, it has led to pest resurgence and reduced efficacy. Botrytis cinereal is one of the major pathogen species that have developed resistance. It affects the production of fruit and vegetable crops both during pre- and post-harvest times. Multi-resistant strains have emerged in various nations as a result of excessive spraying activity. There has been an upsurge in interest in biological control of Botrytis through the use of plant-based products or antagonistic microorganisms, even if biofungicides cannot be compared to chemical protection against the disease. Strains of bacteria (Bacillus spp.) and filamentous fungi (Trichoderma harzianum) are some of the major products being marketed. These products have been proven to be successful in controlling serious leaf and root diseases in crops and are frequently employed in controlled environments. Competitive landscape The global market for biocontrol is dominated by a few players, such as Bayer AG (Germany), Marrone Bio Innovations (US), Corteva Agriscience (US), Shin-Etsu Chemical Co. Ltd. (Japan), Certis USA L.L.C (US), BASF SE (Germany), Valent BioSciences (US), Koppert Biological Systems (Netherlands), Syngenta AG (Switzerland), UPL Limited (India), and FMC Corporation (US). Premium Insights North America to Dominate the Market Europe to Grow at Highest Rate in Terms of Volume Biopesticides to Account for Larger Market During Forecast Period Semiochemicals Were Estimated to Hold a Significant Share in Terms of Volume Demand for Microbials to be Highest During Forecast Period US and Biopesticides Segment Accounted for Significant Shares in North America Italy, US, Spain, and the UK to Grow at Significant Rates During Forecast Period Market Overview
BioControl Frequently Asked Questions (FAQ)
What is BioControl's latest funding round?
BioControl's latest funding round is Other Investors.
Who are the investors of BioControl?
Investors of BioControl include GlenRock Israel and YFM Equity Partners.
Who are BioControl's competitors?
Competitors of BioControl include NeuroPace, Tepha, Noraker, Amaranth Medical, Bio Control Medical and 11 more.
Compare BioControl to Competitors
Kspine is developing implantable medical devices for the treatment of spine disorders.
Astra Tech develops and manufactures advanced healthcare devices and medical implants. The company aims to design products that improve the quality of life of those who use them, and to provide solutions that reduce the overall cost of care. Extensive experience, cross-disciplinary research and strictly controlled clinical trials are central to the company's business. In recent years, the company has invested heavily in integrating medical research with modern materials engineering, creating products with properties.
Freedom Innovations is a high technology provider of premium prosthetic devices, a growing segment of the non-invasive orthopedic market. It deals with making prosthetic devices with latest technological developments and customization for lower limb amputations. The branded carbon fiber foot products lead the industry in reputation and growth rate. The company's first microprocessor-controlled product, the Pli' MPC Knee, was introduced in May 2007, serving as an entry into the SMART technology arena.What aims to make the company and the products is the high customization in the prosthetic devices market ranging from different limbs for swimmers to bikers to soldiers and so on.In February 2012, Health Evolution Partners acquired a majority stake in Freedom Innovations. The valuation of Freedom Innovations was undisclosed. Other terms of the deal were not released.
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.
Artificial Airways is a Texas-based "C" corporation formed to commercialize a range of medical devices developed by Dr. Angel at the UT Health Science Center in San Antonio. Airtificial Airways' devices incorporate "stent" technologies to address critical needs in the performance of existing pulmonary and cardiovascular devices - unmet needs that result in frequent, expensive and life-threatening medical complications.
Afferent Corporation, based in Providence, Rhode Island, is developing of a new class of medical devices to treat chronic neurologic dysfunction. Its lead technology enhances the function of mechanoreceptor cells involved in sensory perception as a means to restore brain function following a stroke, to address complications resulting from diabetic neuropathy, and to improve elderly balance. Afferent's development efforts are being pursued in collaboration with leading biomedical and clinical researchers throughout the United States. Building on this technology platform, Afferent aims to establish a leadership position in the emerging field of neurotherapeutic devices.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.